News

Article

Cambrex Adds Process Development Capabilities

Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility.

Cambrex Corporation announced plans for a $5-million expansion of laboratory facilities at its Karlskoga, Sweden site, which includes additional capability and capacity for process development and scale up, handling of potent substances, crystallization studies, and solid phase characterization. Construction on the three story, 600-sq.-m building will begin at the end of second quarter of 2018, with completion due in the second quarter of 2019, the company reported in a May 31, 2018 press announcement.

The expansion will feature a new technical laboratory with walk-in hoods for laboratory syntheses up to 10 L and will enable handling of potent substances at a large laboratory scale, high-pressure reactions, and parallel synthesis for API route scouting and development.

The expansion also will feature two analytical development and quality control laboratories and office space for 12 scientists and chemists, bringing the total headcount to 60.

Source: Cambrex

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content